Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B

AIM: Phase 2b study to assess efficacy, safety, thrombogenicity, immunogenicity and tolerability with 28 days of daily dosing of subcutaneous (SQ) dalcinonacog alfa as prophylaxis for haemophilia B (HB). METHODS: Adult males with a confirmed diagnosis of congenital HB (factor IX [FIX] activity <2...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlangu, Johnny, Levy, Howard, Lee, Martin, Del Greco, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359950/
https://www.ncbi.nlm.nih.gov/pubmed/33960073
http://dx.doi.org/10.1111/hae.14315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359950/
https://www.ncbi.nlm.nih.gov/pubmed/33960073
http://dx.doi.org/10.1111/hae.14315

Ejemplares similares